Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 6/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049889 | 1.00 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL1059519 | 1.00 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931221 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6927677 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL930664 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL23835494 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL525145 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931219 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL928750 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL929422 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2026-05-26 | — | — | US | claimed |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-01-27 | — | — | US | claimed |
| US-12486178-B2 | Copper nanoclusters, composition comprising the same, and treatment of multiple sclerosis | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2025-12-02 | — | — | US | claimed |
| US-20250249036-A1 | Composition and Method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2025-08-07 | — | — | US | claimed |
| US-12371339-B2 | Copper nanoclusters, thymine-modified hyaluronic acid and poly(copper nanoclusters), method for preparing the same, and application thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2025-07-29 | — | — | US | claimed |
| US-12310985-B2 | Composition and method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY (CN) | 2025-05-27 | — | — | US | claimed |
| US-20240391792-A1 | COPPER NANOCLUSTERS, COMPOSITION COMPRISING THE SAME, AND TREATMENT OF MULTIPLE SCLEROSIS | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2024-11-28 | — | — | US | claimed |
| EP-4135721-B1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2024-11-20 | — | — | EP | claimed |
| CN-113423432-B | Copper clusters, compositions comprising copper clusters, and treatment of neurodegenerative diseases | 武汉广行科学研究有限公司 | 2024-10-29 | — | — | CN | claimed |
| EP-4045063-B1 | COMPOSITION AND METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS | WUHAN VAST CONDUCT SCIENCE FOUND CO LTD (CN) | 2024-10-02 | — | — | EP | claimed |
| CN-111035653-A | Compositions and methods for treating multiple sclerosis | 武汉广行科学研究有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-20200048105-A1 | Substances Containing AuCs and Preparation Method and Use Thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2020-02-13 | — | — | US | claimed |
| US-20190321396-A1 | Substances Containing AuCs and Preparation Method and Use Thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2019-10-24 | — | — | US | claimed |
| EP-3545948-A1 | USE OF GOLD CLUSTER OR GOLD CLUSTER-CONTAINING SUBSTANCE IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING GLAUCOMA | Shenzhen Profound-View Pharma Tech Co., Ltd. (CN) | 2019-10-02 | — | — | EP | claimed |
| US-20190175753-A1 | Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating Glaucoma | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2019-06-13 | — | — | US | claimed |
| US-20190030070-A1 | Substances Containing AuCs and Preparation Method and Use Thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2019-01-31 | — | — | US | claimed |
| US-20190030069-A1 | Substances Containing AuCs and Preparation Method and Use Thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2019-01-31 | — | — | US | claimed |
| CN-101113141-B | Optical active N-(alpha-mercapto radical propionyl group) aminoacetic acid | NANJING SANHOME PHARMACEUTICAL CO LTD | 2011-04-13 | — | — | CN | claimed |
| US-20100204324-A1 | Optically Active N-(Alpha-Mercaptopropionyl)Glycine | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2010-08-12 | — | — | US | claimed |
| EP-2181984-A1 | AN OPTICALLY ACTIVE N- (alpha-MERCAPTOPROPIONY) GLYCINE | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2010-05-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371339-B2 | Copper nanoclusters, thymine-modified hyaluronic acid and poly(copper nanoclusters), method for preparing the same, and application thereof | CD44, UMPS, CSGALNACT1 | ACE 2271/4885KDM4E 4754/4885MAPT 1808/4885 |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | FABP7, FABP4, LIPC | ACE 1483/4885KDM4E 4588/4885MAPT 801/4885 |
| US-20100204324-A1 | Optically Active N-(Alpha-Mercaptopropionyl)Glycine | GNMT, MGST1, GSTP1 | ACE 497/4885KDM4E 4262/4885MAPT 3283/4885 |
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | FABP1, ALB, CSTB | ACE 1412/4885KDM4E 4638/4885MAPT 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.